AMBICION

About:

AMBICION is a pharmaceutical company that develops innovative cancer treatments that address unmet medical needs.

Top Investors: Toho Holdings, REVIC, Regional Health Care Industry Support Fund

Description:

AMBICION develops new drugs focused on establishing a global standard treatment for cancer patients. The company's is called product Natural killer T cells or NKT cells, a type of T cells that also have NK cell properties. It is activated by recognizing glycolipid antigens, produce many types of cytokines, and induce both immunostimulation and suppression reactions. NKT cells can induce cell death to cancer cells due to the nature of NK cells, but its direct cytotoxic activity is limited due to the small amount present in the body. NKT cells also have the ability to produce large amounts of cytokines. AMBICION was founded in October 2015 and is headquartered in Tokyo, Japan.

Total Funding Amount:

660M JPY

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Tokyo, Tokyo, Japan

Founded Date:

2015-10-01

Contact Email:

info(AT)ambicion.co.jp

Founders:

Number of Employees:

1-10

Last Funding Date:

2018-04-18

IPO Status:

Private

Industries: